(Source: Carmat SA) PRESS RELEASE CARMAT subscribes to a contingent equity line Paris, June 12, 2013 CARMAT (FR0010907956, ALCAR), the designer and developer of the world's most advanced total artificial heart project, providing an alternative for people suffering from terminal heart failure, announces that it is taking out a contingent equity line with Kepler Cheuvreux, exercisable by tranches at CARMAT's discretion, as authorised by the Shareholder Meeting of June 4, 2013. CARMAT had a cash position of around 9.2 million euros at the end of May 2013, and expects to receive approximately 6.7 million euros from Oseo in 2013. The Company would thus have around a year of cash at the current...
↧